Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

Search

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

Contents

(Top) 1 References

Oxelumab

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "Oxelumab" – news · newspapers · books · scholar · JSTOR (January 2024)

Oxelumab

Monoclonal antibody

Whole antibody

OX-40 ligand

Clinical data

none

Identifiers

1186098-83-8^N

none

67GFR7JCMN

Chemical and physical data

C₆₄₂₄H₉₉₂₀N₁₇₀₄O₂₀₁₄S₄₂

144594.46 g·mol⁻¹

^NY (what is this?) (verify)

Oxelumab is a human monoclonal antibody designed for the treatment of asthma.^[1]

Oxelumab was developed by Genentech and co-developed by Roche.

References[edit]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab" (PDF). American Medical Association. Archived from the original (PDF) on 12 May 2013.

Monoclonal antibodies for the immune system

Human

Immunosuppression: Abrilumab

Camidanlumab tesirine

Combination: Nivolumab/relatlimab

Mouse

Afelimomab

Telimomab aritox

Zolimomab aritox

Andecaliximab^†

Immunosuppressive: Apolizumab^§

Camrelizumab^†

Certolizumab pegol

Etrolizumab^†

Lampalizumab^†

Ligelizumab^†

Lulizumab pegol

Spartalizumab^†

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized

Otelixizumab

Rozanolixizumab

Human

Bermekimab

Humanized

Anrukinzumab

Mirikizumab^†

Veterinary

Lokivetmab

Inflammatory lesions

Mouse

Besilesomab

Fanolesomab^‡

^#WHO-EM

^‡Withdrawn from market

Clinical trials:

^†Phase III

^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

t

e

This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

t

e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxelumab&oldid=1197554841" Categories: ●Drugs not assigned an ATC code ●Drugs developed by Hoffmann-La Roche ●Drugs developed by Genentech ●Experimental drugs ●Monoclonal antibody stubs ●Antineoplastic and immunomodulating drug stubs Hidden categories: ●Articles needing additional references from January 2024 ●All articles needing additional references ●Articles with short description ●Short description is different from Wikidata ●Articles with changed CASNo identifier ●Chemicals that do not have a ChemSpider ID assigned ●Articles without EBI source ●Chemical pages without DrugBank identifier ●Articles without KEGG source ●Articles without InChI source ●Drugs with no legal status ●Drugboxes which contain changes to verified fields ●Drugboxes which contain changes to watched fields ●Drugs that are a monoclonal antibody ●All stub articles ●This page was last edited on 21 January 2024, at 01:04 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view